Skip to main
IVA

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA is focused on developing lanifibranor, a candidate therapy for non-alcoholic steatohepatitis (NASH), with promising clinical results indicating significant efficacy in improving both fibrosis and metabolic markers in patients. The company's strong financial outlook is supported by research partnerships with AbbVie and BI, which contribute to its revenue stream and validate its research efforts. Additionally, positive clinical trial outcomes suggest that lanifibranor could be a leading treatment option in the NASH landscape, potentially enhancing market penetration and increasing adoption in clinical settings.

Bears say

Inventiva SA, a biopharmaceutical company focused on developing therapies for NASH and other conditions, reported a significant net loss of €175.9 million, translating to €1.62 per share, highlighting financial challenges amid ongoing clinical developments. The company's primary clinical candidate, lanifibranor, is in Phase III trials, with any safety or efficacy issues potentially having detrimental effects on stock performance, particularly in a competitive landscape where existing treatments have been characterized as underwhelming. Additional risks include possible clinical trial failures, delays in regulatory timelines, and difficulties in securing financing, which together contribute to a cautious outlook on the company's future financial stability.

Inventiva S.A. (IVA) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Buy based on their latest research and market trends.

According to 8 analysts, Inventiva S.A. (IVA) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.